We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Troriluzole

News List

Biohaven Provides Update on Phase 2/3 Trial, Alzheimer's Program americanpharmaceuticalreview
January 20, 2021
Biohaven Pharmaceutical has completed a focused analysis of the topline co-primary and key secondary data from its Phase 2/3 clinical trial of troriluzole as a symptomatic treatment in mild-to-moderate Alzheimer's disease (AD).
Biohaven Begins Phase 3 Troriluzole Trial for Obsessive-Compulsive Disorder americanpharmaceuticalreview
January 11, 2021
Biohaven has commenced enrollment in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in patients with obsessive-compulsive disorder (OCD).
Biohaven Announces Issuance of Composition of Matter Patent on Troriluzole by the USPTO americanpharmaceuticalreview
December 11, 2019
Biohaven Pharmaceutical announced the U.S. Patent and Trademark Office (USPTO) issued U.S. Pat. No. 10,485,791 on November 26, 2019 relating to troriluzole.